Presentation is loading. Please wait.

Presentation is loading. Please wait.

Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events

Published byThibaud Brousseau Modified over 5 years ago

Similar presentations

Presentation on theme: "Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events"— Presentation transcript:

1 Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events
Vaccine Adverse Event Reporting System (VAERS) John Iskander MD MPH Immunization Safety Office

2 Safety Data for HPV4: Learning Objective
Participants will be able to describe adverse events (AEs) most commonly reported to the Vaccine Adverse Event Reporting System (VAERS) following quadrivalent human papillomavirus (HPV4) (types 6,11,16,18) recombinant vaccine.

3 Safety Data for HPV4: Outline
VAERS background Overview of all HPV4 Adverse Event Reports HPV4 Adverse Event Reports among females aged 9-26 years HPV4 safety data compared to other adolescent vaccinations among females aged 9-26 year

4 VAERS Overview A national vaccine safety surveillance program
co-managed by CDC and FDA collects and analyzes information from reports of possible adverse events following immunization helps to ensure that the benefits of immunizations continue to be far greater than the risks National in scope covering a diverse population Useful for generating signals for new, unusual, or rare events

5 Safety Data for HPV4: Adverse Events Reported to VAERS
852 total reports received as of February 27, 2007 > 3.2 million doses distributed through January 2007 Demographics 96% (n=816) females 36% (n=310) persons aged years 33% (n=280) persons aged 6-17 years 28% (n=236) age unknown

6 Safety Data for HPV4: Adverse Events Reported to VAERS
Onset interval 39% (n=334) day of vaccination (day 0) 11% (n=97) day 1 34% (n=289) unknown interval Range 0 to over 120 days; median <1 day Recovery 46% (n=388) recovered 30% (n=258) unknown recovery status Source of reports 77% (n=652) vaccine manufacturer 9% (n=76) provider

7 Safety Data for HPV4: Most frequently reported terms
MedDRA Term n % based on N = 852 Dizziness 96 11 Syncope 92 Injection Site Pain 88 10 Pain 73 9 Nausea 72 More than one code may be assigned to a single event.

8 Safety Data for HPV4: Co-administered Vaccines
% Based on N=852 HPV4 alone 752 88 HPV4 and MNQ 16 2 Hep A and HPV4 11 1 Flu and HPV4 10 HPV4 and Tdap 8

9 Safety Data for HPV4: Serious Reports*
88% (36/41) HPV4 alone No deaths 37% (15/41) required hospitalization Recovery 39% (16/41) recovered 37% (15/41) patient had not recovered * Defined by Code of Federal Regulations as involving hospitalization, death, disability, life threatening illness, or certain other medically important conditions

10 Safety Data for HPV4: Most frequently reported serious terms
MedDRA Term n % Based on N=41 Computerized Tomogram Normal 7 17 Vomiting 6 15 Nausea Dehydration 5 12 Pyrexia Dizziness More than one code may be assigned to a single event.

11 Safety Data for HPV4: Guillain Barré Syndrome
3 reports of GBS after HPV4 13 y/o onset 8 days; received PPV within 30 days of HPV4; unknown recovery status 16 y/o onset unknown; received HPV4 alone; not recovered at time report submitted 13 y/o onset 13 days; received MNQ and HPV4 at the same time; unknown recovery status

12 Safety Data for HPV4: Adverse Events Reported to VAERS Females ages 9-26
567 total reports as of Feb 27, 2007 Onset interval 46% (n=259) day of vaccination (day 0) 14% (n=81) day 1 19% (n=108) unknown onset interval Range: 0 to over 120 days; median 0 days (day of vaccination)

13 Safety Data for HPV4: Most frequently reported terms Females ages 9-26
As coded using the MedDRA preferred terms. More than one code may be assigned to a single event MedDRA Term n % Based on N=567 Dizziness 70 12 Nausea 55 10 Injection Site Pain 53 9 Pain 52 Syncope 49

14 Safety Data for HPV4: Serious Events* Females ages 9-26
6% (41/567) serious reports 86% (36/41) HPV4 alone 36% (36/41) required hospitalization Recovery 44% (16/41) recovered 39% (14/41) not recovered * Defined by Code of Federal Regulations as involving hospitalization, death, disability, life threatening illness, or certain other medically important conditions

15 Safety Data for HPV4: Most frequently reported serious terms Females ages 9-26
MedDRA Term n % Based on N=36 Computerized Tomogram Normal 7 19 Vomiting 6 17 Dehydration 5 14 Pyrexia Nausea More than one code may be assigned to a single event.

16 Safety Data for HPV4: Syncope Females ages 9-26
55 reports 82% (n=45) HPV4 alone 6% (n=3) serious Onset 66% (n=36) day of vaccination (day 0) 29% (n=16) day 1 Recovery 58% (n=32) recovered 29% (n=16) unknown recovery

17 Safety Data for HPV4: Syncope and other Adolescent Vaccines Females ages 9-26
Hepatitis B (N=5298) 297 reports 51% (n=151) Hep B alone 7% (n=21) serious Menactra (MCV4) (N=570) 30 reports 43% (n=13) MCV4 alone No serious reports Tdap (N=396) 24 reports 33% (n=8) Tdap alone

18 Safety Data for HPV4: Common Adverse Event Comparison Females ages 9-26
HPV4 (N=567) % Menactra (N=570) Tdap (N=396) Hep B (N=5298) Dizziness 12 13 11 Injection Site Pain 9 8 Pain 17 15 Syncope 5 6

19 Limitations of VAERS Limitations
Underreporting (differential reporting) Preferential reporting of events proximal to immunization Inaccurate, or incomplete information Stimulated reporting No basis for calculating incidence rates of adverse events

20 Conclusion Overall HPV4 has a favorable safety profile; there have been few serious reports The proportion of syncope reports is slightly higher in females ages 9-26 who received HPV4 compared to other vaccines Providers should follow ACIP recommendations for prevention of accidents due to syncope following vaccination: Providers should *strongly consider observing patients for 15 minutes after they are vaccinated. If syncope develops, patients should be observed until the symptoms resolve. Centers for Disease Control and Prevention. General Recommendations on Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2006; 55; 1-48.

21 Background Slides

22 Safety Data for HPV4: Adverse Events Reported to VAERS Females ages 9-26
Recovery 48% (n=270) reported recovered at time report submitted 25% (n=140) unknown 24% (n=137) reported not recovered at time report submitted Source of reports 69% (n=390) vaccine manufacturer 12% (n=66) provider

23 Safety Data for HPV4: Co-administered Vaccines Females ages 9-26
% Based on N=567 HPV4 alone 484 85 HPV4 and MNQ 16 3 Hep A and HPV4 11 2 Flu and HPV4 10 HPV4 and Tdap 7 1

24 Safety Data for HPV4: Injection Site Pain Females ages 9-26
50 reports 86% (n=43) HPV4 alone 2% (n=1) serious Onset interval 52% (n=26) day of vaccination (day 0) 10% (n=5) day 1 Recovery 42% (n=21) recovered 34% (n=17) unknown recovery

25 Injection Site Pain and other Adolescent Vaccines Females ages 9-26
Hepatitis B 408 reports 63% (n=258) Hep B alone 3% (n=11) serious Menactra 44 reports 59% (n=26) MCV4 alone 2% (n=1) serious Tdap 46 reports 67% (n=31) Tdap alone

26 Safety Data for HPV4 Common Adverse Event Comparison Females ages 9-26
HPV4 (N=567) n % Menactra (N=570) Tdap (N=396) n % Hep B (N=5298) n % Dizziness 70 12 71 13 49 569 11 Injection site pain 53 9 44 8 46 412 Pain 52 99 17 59 15 463 Syncope 30 5 20 289 6

Download ppt "Quadrivalent Human Papillomavirus Vaccine (HPV4) Adverse Events"

Similar presentations

The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.

The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
Julianne Gee, MPH Immunization Safety Office

Julianne Gee, MPH Immunization Safety Office
1 VAERS Reporting During a Large Scale Vaccination Clinic in Chicago Lessons Learned Chicago Department of Public Health Immunization Program Lorraine.

1 VAERS Reporting During a Large Scale Vaccination Clinic in Chicago Lessons Learned Chicago Department of Public Health Immunization Program Lorraine.
Hepatitis web study H EPATITIS W EB S TUDY Hepatitis A: Epidemiology Presentation Prepared by: David Spach, MD and Nina Kim, MD Last Updated: May 31, 2011.

Hepatitis web study H EPATITIS W EB S TUDY Hepatitis A: Epidemiology Presentation Prepared by: David Spach, MD and Nina Kim, MD Last Updated: May 31, 2011.
Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.

Module 6 Inactivated poliovirus vaccine AEFI monitoring Training for Inactivated Poliovirus Vaccine (IPV) introduction.
Vaccine Safety Concerns  Past of vaccines  Now most parents have never seen a case of diphtheria, measles, or other once- common diseases.  They therefore.

Vaccine Safety Concerns  Past of vaccines  Now most parents have never seen a case of diphtheria, measles, or other once- common diseases.  They therefore.
What's New on the Child and Adolescent Immunization Schedules William L. Atkinson, MD, MPH National Center for Immunization and Respiratory Diseases William.

What's New on the Child and Adolescent Immunization Schedules William L. Atkinson, MD, MPH National Center for Immunization and Respiratory Diseases William.
Jeff Neccuzi, Director Division of Immunization Services WV Bureau for Public Health.

Jeff Neccuzi, Director Division of Immunization Services WV Bureau for Public Health.
1 1 Immunization Update 2011 Connecticut Immunization Teleconference April 19, 2011 William Atkinson, MD, MPH National Center for Immunization and Respiratory.

1 1 Immunization Update 2011 Connecticut Immunization Teleconference April 19, 2011 William Atkinson, MD, MPH National Center for Immunization and Respiratory.
VAERS Analysis SaneVax Inc. ©2012. Total Adverse Events Gardasil (HPV4)was approved for use in June 2006. This chart represents the vaccines most frequently.

VAERS Analysis SaneVax Inc. ©2012. Total Adverse Events Gardasil (HPV4)was approved for use in June This chart represents the vaccines most frequently.
The National Vaccine Plan Process - Update October 22, 2007 Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human Services.

The National Vaccine Plan Process - Update October 22, 2007 Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human Services.
1 Universal Immunization Against Rare Diseases  How much is a child’s life worth?  The individual vs society.

1 Universal Immunization Against Rare Diseases  How much is a child’s life worth?  The individual vs society.
1 LYMErix® Safety Data Reported to the Vaccine Adverse Event Reporting System (VAERS) Robert Ball, M.D., M.P.H., Sc.M. Division of Epidemiology Office.

1 LYMErix® Safety Data Reported to the Vaccine Adverse Event Reporting System (VAERS) Robert Ball, M.D., M.P.H., Sc.M. Division of Epidemiology Office.
Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , 2012-13 Kelley Bemis, MPH CDC/CSTE Applied.

Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , Kelley Bemis, MPH CDC/CSTE Applied.
State Health Agency Perspectives on the Implementation of New Vaccines Presentation to the National Vaccine Advisory Committee September 26, 2006 Calvin.

State Health Agency Perspectives on the Implementation of New Vaccines Presentation to the National Vaccine Advisory Committee September 26, 2006 Calvin.
1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.

1 Vaccines and Related Biologic Products Advisory Committee (VRBPAC) May 16, 2007 FluMist ® Influenza Virus Vaccine Live, Intranasal Safety and Effectiveness.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.

Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
Immunization Safety System- Registry Linkages: Lessons Learned from the Smallpox Vaccination Program John Iskander, David Walker, Roseanne English-Bullard,

Immunization Safety System- Registry Linkages: Lessons Learned from the Smallpox Vaccination Program John Iskander, David Walker, Roseanne English-Bullard,
Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.
Vaccination Administration Errors Reported to the Vaccine Adverse Event Reporting System (VAERS) Elaine R. Miller, RN, MPH Beth Hibbs, RN, MPH Barbara.

Vaccination Administration Errors Reported to the Vaccine Adverse Event Reporting System (VAERS) Elaine R. Miller, RN, MPH Beth Hibbs, RN, MPH Barbara.

Similar presentations

Ads by Google